• 3 May 2019

    April’s top news stories

    Chinese clinical-stage biopharmaceutical company I-Mab Biopharma and German biotech company MorphoSys have begun the first dosed Phase III clinical study to assess investigational human CD38 antibody TJ202/MOR202 in combination with...

  • 5 April 2019

    March’s top news stories

    Aldeyra Therapeutics reported positive data from the Phase III ALLEVIATE trial that evaluated the efficacy and safety of 0.25% and 0.5% concentrations of reproxalap topical ophthalmic solution to treat patients...

  • 5 March 2019

    February’s top news stories

    Eidos Therapeutics commenced a pivotal Phase III clinical trial of its investigational small molecule AG10 for the treatment of transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM), and Immatics is set to study...

  • 6 February 2019

    Sandoz Abandons US Development of Rixathon

    Chloé Thépaut, MRes, Oncology Senior Analyst, GlobalData, examines the implications of Sandoz’s abandoned attempt to have Rixathon approved in the US

  • 5 February 2019

    January’s top news stories

    Janssen Pharmaceutical Companies of Johnson & Johnson unblinded the Phase III TITAN trial investigating Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic...


Go Top